Last reviewed · How we verify
SHR-A1811 combined with Pyrotinib.
SHR-A1811 combined with Pyrotinib. is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | SHR-A1811 combined with Pyrotinib. |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer (PHASE2)
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study (PHASE2)
- A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane (PHASE3)
- This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy. (PHASE2)
- Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis (PHASE1, PHASE2)
- A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. (PHASE1, PHASE2)
- A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients (PHASE2)
- A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-A1811 combined with Pyrotinib. CI brief — competitive landscape report
- SHR-A1811 combined with Pyrotinib. updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about SHR-A1811 combined with Pyrotinib.
What is SHR-A1811 combined with Pyrotinib.?
SHR-A1811 combined with Pyrotinib. is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd..
Who makes SHR-A1811 combined with Pyrotinib.?
SHR-A1811 combined with Pyrotinib. is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).
What development phase is SHR-A1811 combined with Pyrotinib. in?
SHR-A1811 combined with Pyrotinib. is in Phase 1.